Editas Medicine, Inc. (NASDAQ:EDIT) will be announcing its earnings results after the market closes on Monday, November 6th. Analysts expect the company to announce earnings of ($0.60) per share for the quarter.

Editas Medicine (NASDAQ:EDIT) last released its quarterly earnings data on Wednesday, August 9th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.01). The business had revenue of $3.10 million for the quarter, compared to analyst estimates of $2.20 million. Editas Medicine had a negative return on equity of 67.75% and a negative net margin of 2,091.36%. Editas Medicine’s revenue was down 8.8% compared to the same quarter last year. During the same quarter last year, the company earned ($0.54) EPS. On average, analysts expect Editas Medicine to post $-2.88 EPS for the current fiscal year and $-2.89 EPS for the next fiscal year.

Shares of Editas Medicine, Inc. (EDIT) opened at 22.28 on Monday. The firm’s market cap is $911.83 million. The company’s 50-day moving average is $22.87 and its 200 day moving average is $22.87. Editas Medicine, Inc. has a 1-year low of $12.43 and a 1-year high of $29.20.

TRADEMARK VIOLATION NOTICE: “Editas Medicine, Inc. (EDIT) to Release Quarterly Earnings on Monday” was posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/30/editas-medicine-inc-edit-to-release-quarterly-earnings-on-monday.html.

Several brokerages have recently weighed in on EDIT. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Editas Medicine in a research report on Tuesday, July 18th. Cann reiterated a “hold” rating on shares of Editas Medicine in a research report on Thursday, August 10th. Barclays PLC began coverage on shares of Editas Medicine in a research report on Wednesday, September 6th. They set an “overweight” rating and a $28.00 target price on the stock. SunTrust Banks, Inc. began coverage on shares of Editas Medicine in a research report on Thursday, July 13th. They set a “hold” rating and a $17.00 target price on the stock. Finally, Zacks Investment Research upgraded shares of Editas Medicine from a “sell” rating to a “hold” rating in a research report on Monday, October 16th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $25.88.

In other Editas Medicine news, insider Katrine Bosley sold 8,333 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $24.78, for a total value of $206,491.74. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders sold 51,665 shares of company stock worth $1,083,165. Company insiders own 19.40% of the company’s stock.

About Editas Medicine

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Earnings History for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.